A STUDY TO COMPARE THE PHARMACOKINETICS OF PF-06835919 IN PARTICIPANTS WITH AND WITHOUT HEPATIC IMPAIRMENT
Condition: Hepatic Impairment; Healthy Participants
MeSH terms: Liver Diseases
Intervention: PF-06835919 25 mg
Intervention description: PF-06835919 in 25 mg oral tablet will be administered on Day 1
Phase: Phase 1
Study type: Interventional
Primary purpose: Basic Science
Allocation: Non-Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Enrollment: 23.0
Sex: All
Minimum age: 18 Years
Maximum age: 70 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: Non-alcoholic Fatty Liver Disease; Non-alcoholic steatohepatitis

Summary:

      The study is proposed to characterize the effect of varying degrees of hepatic impairment on
      the plasma PK of PF-06835919
    

Eligibility criteria:

        Inclusion Criteria:

          -  Male and female participants between the ages of 18 (or the minimum country specific
             age of consent if >18) and 70 years, inclusive, at the Screening visit:

          -  Participants who are willing and able to comply with all scheduled visits, treatment
             plan, laboratory tests, lifestyle considerations, and other study procedures.

          -  Body mass index (BMI) of 17.5 to 35.4 kg/m2; and a total body weight >50 kg (110 lb).

          -  Capable of giving signed informed consent, which includes compliance with the
             requirements and restrictions listed in the informed consent document (ICD) and in
             this protocol.

        Exclusion Criteria:

          -  Any condition possibly affecting drug absorption (eg, prior bariatric surgery,
             gastrectomy, ileal resection).

        (Participants who have undergone cholecystectomy and/or appendectomy are eligible for this
        study as long as the surgery occurred more than 6 months prior to Screening)..

          -  At Screening, participants with a positive result for human immunodeficiency virus
             (HIV) antibodies, as assessed by sponsor identified central laboratory, with a single
             repeat permitted to assess eligibility, if needed.

          -  Other acute or chronic medical or psychiatric condition including recent (within the
             past year) or active suicidal ideation or behaviour or laboratory abnormality that may
             increase the risk associated with study participation or investigational product
             administration or may interfere with the interpretation of study results and, in the
             judgment of the investigator, would make the participant inappropriate for entry into
             this study.

          -  Use of prior/concomitant therapies.

          -  Previous administration with an investigational drug within 30 days (or as determined
             by the local requirement) or 5 half lives preceding the first dose of investigational
             product used in this study (whichever is longer).

          -  Participants with known prior participation (ie, randomized and received at least 1
             dose of investigational product) in a study involving PF 06835919.

          -  A positive urine drug test, for illicit drugs, and/or a positive breath alcohol test
             at Screening. However, participants who have been medially prescribed opiates/opiods
             or benzodiazepines and report the use of these drugs to the investigator at the
             screening visit will be allowed to participate.

          -  Male participants with partners who are currently pregnant.

          -  Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more
             within 60 days prior to dosing and until the follow-up contact.

          -  History of sensitivity to heparin or heparin induced thrombocytopenia, only if heparin
             is used to flush intravenous catheters used during serial blood collections.

          -  Unwilling or unable to comply with the criteria in the Lifestyle Considerations
             section of the protocol.

          -  Investigator site staff members directly involved in the conduct of the study and
             their family members, site staff members otherwise supervised by the investigator, or
             Pfizer employees, including their family members, directly involved in the conduct of
             the study.